Pharmacokinetic-pharmacodynamic (PK-PD) modeling has emerged as a major tool in clinical pharmacology to optimize drug\r\nuse by designing rational dosage forms and dosage regimes. Quantitative representation of the dose-concentration-response\r\nrelationship should provide information for the prediction of the level of response to a certain level of drug dose. This paper\r\ndescribes the experimental details of the preformulation study, tablet manufacture, optimization, and bioanalytical methods for\r\nthe estimation of dexibuprofen in human plasma. The hydrophilic matrix was prepared with xanthen gum with additives Avicel\r\nPH 102. The effect of the concentration of the polymer and different filler, on the in vitro drug release, was studied. Various\r\npharmacokinetic parameters including AUC0ââ?¬â??t, AUC0ââ?¬â??8, Cmax, Tmax, T1/2, and elimination rate constant (Kel) were determined\r\nfrom the plasma concentration of both formulations of test (dexibuprofen 300 mg) and reference (dexibuprofen 300 mg tablets).\r\nThe merits of PK-PD in the development of dosage forms and how PK-PD model development necessitates the development of\r\nnew drugs and bio analytical method development and validation are discussed. The objectives of the present study, namely, to\r\ndevelop and validate the methods to estimate the selected drugs in the biological fluids by HPLC, the development of in vitro\r\ndissolution methods, and PK-PD model development have been described.
Loading....